2024-09-16

INSIDE INFORMATION - UPDATE ON GLOBAL REGISTRATIONAL STRATEGY FOR IMM2510 FOR NON-SMALL CELL LUNG CANCER AND TRIPLE-NEGATIVE BREAST CANCER

2024-09-13

VOLUNTARY ANNOUNCEMENT - TRANSFER OF EQUITY INTEREST IN A SUBSIDIARY

2024-09-11

VOLUNTARY ANNOUNCEMENT - FURTHER PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510 AND IMM27M

2024-09-10

VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENTS

2024-09-04

Next Day Disclosure Return

2024-09-04

INSIDE INFORMATION - COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY

2024-09-04

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2024

2024-09-03

INSIDE INFORMATION - THE H SHARE FULL CIRCULATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE

2024-08-26

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024

2024-08-22

VOLUNTARY ANNOUNCEMENT - UPFRONT PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510 AND IMM27M

2024-08-14

DATE OF BOARD MEETING

2024-08-06

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2024

2024-08-01

INSIDE INFORMATION - LICENSE AND COLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510 AND IMM27M

2024-07-30

(1) RESIGNATION OF SUPERVISOR; AND (2) ELECTION OF EMPLOYEE REPRESENTATIVE SUPERVISOR

2024-07-24

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM27M

2024-07-05

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2024

2024-07-03

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH TISLELIZUMAB

2024-06-21

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMC-002

2024-06-05

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2024

2024-06-03

VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR A PHASE III CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE FOR THE FIRST-LINE TREATMENT OF CMML